search

Qilu Pharmaceutical Acquired an Exclusive Right for the Development and Commercialization of Vicineum™ in Greater China

ABOUT US

图片名称

Qilu Pharmaceutical Acquired an Exclusive Right for the Development and Commercialization of Vicineum™ in Greater China


Release time:

2021-07-31

Qilu Pharmaceutical announced an exclusive license agreement with Sesen Bio for the development and commercialization of Vicineum™ in Greater China on July 31st, 2020. Vicineum™ is used for the treatment of BCG-unresponsive non-muscle invasive bladder cancer (“NMIBC”) and other types of cancer.

“Qilu is well-respected for their commercialization and manufacturing expertise, and this partnership marks an important milestone in realizing what we believe to be a significant market opportunity for Vicineum” said Dr. Thomas Cannell, president and chief executive officer of Sesen Bio.

“Sesen is the ideal partner for us with the unique scientific research advantage in NMIBC” said Yan Li, chief executive officer of Qilu Pharmaceutical. “We look forward to working with Sesen and The National Medical Products Administration to bring Vicineum to patients who urgently need better therapies for BCG unresponsive non-muscle invasive bladder cancer in China.”

齐鲁制药有限公司
齐鲁制药有限公司
齐鲁制药有限公司

 

Tel: +86-531-83127705831277048312770683127711

Address: 8888 Lvyou Road, High-tech Zone, Jinan, 250104, China

Email:export@qilu-pharma.com


监督举报

亲爱的合作伙伴:

欢迎举报以下行为!

索贿、暗箱操纵招标、内定中标单位、员工或亲属参与公司业务往来牟取私利、偷工减料、以次充好、故意刁难供应商等行为。

举报电话:0531-83126898/55820713/83126871

举报邮箱:qljc@qilu-pharma.com

收信地址:山东省济南市历城区旅游路8888号

齐鲁制药集团审计监察部

采购平台技术专线